| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | Dec 17, 2025 | Rezolute, Inc. | Director | Buy | 82.5 | +5,650 | 4.96% | ✗ | $9.5K |
| Mar 31, 2025 | Apr 1, 2025 | Rezolute, Inc. | Director | Buy | 86.3 | +6,758 | 8.75% | ✗ | $19.7K |
| Feb 16, 2025 | Feb 20, 2025 | Rezolute, Inc. | Director | Buy | 91.3 | +35,500 | 85.00% | ✗ | $47K |
| Sep 24, 2024 | Sep 24, 2024 | Rezolute, Inc. | Director | Buy | 91.3 | +4,259 | 11.35% | ✗ | $20K |
| Jun 25, 2024 | Jun 27, 2024 | Rezolute, Inc. | Director | Buy | 91.3 | +4,815 | 14.73% | ✗ | $20K |
| Oct 15, 2021 | May 6, 2022 | Rezolute, Inc. | Director | Buy | 95.0 | +32,693 | 100.00% | ✗ | $145K |
| Oct 4, 2019 | Oct 7, 2019 | Ultragenyx Pharmaceutical Inc. | COO | Sell | 42.5 | -1,297 | -6.49% | ✗ | $57.7K |